i
Post-licensure safety surveillance of 20-valent pneumococcal conjugate vaccine (PCV20) among U.S. adults in the Vaccine Adverse Event Reporting System (VAERS)
-
February 29, 2024
-
Series: ACIP meeting Influenza
[PDF-545.50 KB]
Details:
Related Documents
-
- Personal Author:Self, Wesley H. ;Rouphael, Nadine...February 29, 2024 | ACIP meeting Pneumococcal VaccinesDescription:Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USAhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-...Personal Author:Das, RituparnaFebruary 29, 2024 | ACIP meeting Respiratory Syncytial Virus (RSV) Older Adults VaccineDescription:The safety and efficacy of this investigational RSV vaccine have not been established in any country for any use02-RSV-Adults-Das-508.pdf